Top 10 Breast Cancers in WomencancerIt ranks first, and ranks fourth in cancer mortality in 2020. In the past five years, more than 7.8 million women have been diagnosed with breast cancer, and recent research by the University of Washington has good news. Latest research and development of the schoolVaccinationIt has passed phase 1 clinical trials and is expected to become popular in the future.
According to the World Health Organization, 2.3 million women will be diagnosed with breast cancer in 2020, and 7.8 million women have been diagnosed in the past five years, with 1% of those diagnosed in men. But in the majormedicineAccording to the latest Phase 1 clinical trial data, the safety of the new vaccine appears to be stable, and many breast cancer patients have had positive reactions such as an enhanced immune response after vaccination.
In an interview with Medical News Today, Dr. Kotryna Temsinaite, Research Communications Manager for Breast Cancer Now, explained that the treatment process for breast cancer is very difficult, and treatment is different for each person based on their symptoms. This is the reason why the premier hospital is working on the development of various treatments and vaccines.
The vaccine study, led by Dr. Mary Nora L. Dissis of the Cancer Vaccine Institute at the University of Washington Medicine, said the vaccine generated a strong immune response to the key tumor cell protein ERBB2. The results of the study have also been published in the journal JAMA Oncology.
During the research, the pilot team tested 66 patients with advanced breast cancer between the ages of 34 and 77, and were followed from January 2012 to March 2013 and from July 2021 to August 2022 in the trial results .
Participants received regular monthly doses of 10ug, 100ug, or 500ug of plasmid DNA vaccine over the course of three months of the experiment. The researchers then measured blood immunity, vaccine toxicity and biopsy samples at set time points to assess the persistence of the vaccine’s DNA. During the experiment, it was also found that 33% of the subjects had flu-like symptoms and 36% had symptoms of fatigue. Those who received both the 100 µg and 500 µg vaccine doses had a stronger immune response than those given the 10 µg dose, while there was no significant difference between 100 µg and 500 µg.
Dias explained that one of the main points of desire to develop a vaccine is that after breast cancer treatment is over, it is often found that there are a small number of cancer cells in the body that have not been detected, which can lead to recurrence. Can And this vaccine will stimulate the T cells, so that the cells are programmed to hunt down that cluster of cancer cells, find all the remaining cancer cells in the body, and kill them all.
Dr. Bhavna Pathak, hematologic medical oncologist at the Cancer Institute of Orange Coast Medical Center in California, said that ideally, people should prevent cancer before it becomes cancer. The current hepatitis B vaccine for hepatocellular carcinoma, and the vaccine for cervical cancer. Cancer HPV vaccines have good efficacy and potency.
Ticinati believes that although the vaccine has some potential to treat breast cancer, it is only in the experimental stage, and the associated side effects and whether it will have a true immunosuppressive effect are still to be studied. Despite this, both Dias and Bata take a positive view on vaccines, and believe that breast cancer vaccines are likely to actually be used in clinical practice within five years. Once the vaccine is proven to be effective, it will be a great boon for patients in the future, and I am sure it will save a lot of treatment time.
Dias also said that the Medical Cancer Vaccine Institute of the University of Wisconsin (Wisconsin), where he works, has developed vaccines for various cancers, such as breast cancer, ovarian cancer, colon cancer, prostate cancer and bladder cancer, in a sequential manner. have studied. However, the breast cancer vaccine is still under investigation at this stage, and the experimental team will randomly assign patients in a phase II study to receive either the vaccine or the immune stimulant to test whether it can treat the disease. can prevent recurrence.